Collegium Pharmaceutical Announces FDA Approval Of AllerNaze™, A Nasal Inhaled Steroid For The Treatment Of Allergic Rhinitis
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older.
Monday, January 12, 2009
National Oncologic PET Registry And Supporting Organizations, Including SNM, Continue To Advocate Cancer Coverage
National Oncologic PET Registry And Supporting Organizations, Including SNM, Continue To Advocate Cancer Coverage
The Centers for Medicare and Medicaid Services (CMS) have released a draft of their proposed positron emission tomography (PET) national coverage determination (NCD). This proposed legislation would allow for reimbursement of PET by the federal government for patients with all types of cancer. The proposed decision expands coverage to include cancer staging and restaging, in addition to initial diagnosis.
A Cell's Inactive State Is Critical For Effectiveness Of Cancer Treatment
A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
Defining Increased Future Risk For Prostate Cancer: Evidence From A Population Based Screening Cohort
UroToday.com - For men with a relatively low PSA on prostate cancer (CaP) screening, what is their risk on future screening exams of having CaP detected? This question was addressed by Dr. Fritz Schröder and collaborators in the online edition of the Journal of Urology. Their work used the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) database.
Hospital First In US To Treat Kidney Tumor With New Device Using Electrical Pulses
On Thursday, January 8, Rhode Island Hospital treated an inoperable kidney tumor using a new technology known as NanoKnife. Damian Dupuy, MD, director of ablation services at Rhode Island Hospital and a national pioneer in ablation treatment, performed the procedure -- the first time it has been used on a kidney tumor in the United States.
Mount Sinai Medical Center Hosts 'Man To Man' Prostate Cancer Education And Support Meetings
There's no question that three of the most terrifying words in the English language are "You have cancer." For a man, add the word "prostate" and the fear factor rises even higher, since prostate cancer is the second leading cause of cancer-related death in men. Dr. David B.
Collegium Pharmaceutical Announces FDA Approval Of AllerNaze™, A Nasal Inhaled Steroid For The Treatment Of Allergic Rhinitis
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older.
The Centers for Medicare and Medicaid Services (CMS) have released a draft of their proposed positron emission tomography (PET) national coverage determination (NCD). This proposed legislation would allow for reimbursement of PET by the federal government for patients with all types of cancer. The proposed decision expands coverage to include cancer staging and restaging, in addition to initial diagnosis.
A Cell's Inactive State Is Critical For Effectiveness Of Cancer Treatment
A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
Defining Increased Future Risk For Prostate Cancer: Evidence From A Population Based Screening Cohort
UroToday.com - For men with a relatively low PSA on prostate cancer (CaP) screening, what is their risk on future screening exams of having CaP detected? This question was addressed by Dr. Fritz Schröder and collaborators in the online edition of the Journal of Urology. Their work used the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) database.
Hospital First In US To Treat Kidney Tumor With New Device Using Electrical Pulses
On Thursday, January 8, Rhode Island Hospital treated an inoperable kidney tumor using a new technology known as NanoKnife. Damian Dupuy, MD, director of ablation services at Rhode Island Hospital and a national pioneer in ablation treatment, performed the procedure -- the first time it has been used on a kidney tumor in the United States.
Mount Sinai Medical Center Hosts 'Man To Man' Prostate Cancer Education And Support Meetings
There's no question that three of the most terrifying words in the English language are "You have cancer." For a man, add the word "prostate" and the fear factor rises even higher, since prostate cancer is the second leading cause of cancer-related death in men. Dr. David B.
Collegium Pharmaceutical Announces FDA Approval Of AllerNaze™, A Nasal Inhaled Steroid For The Treatment Of Allergic Rhinitis
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved AllerNaze™ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve (12) years of age and older.
Subscribe to:
Posts (Atom)
